Deacon Dekker C, Smith Eric A, Judson-Torres Robert L
Department of Dermatology, University of Utah, Salt Lake City, UT, United States.
Department of Pathology, University of Utah, Salt Lake City, UT, United States.
Front Med (Lausanne). 2021 Apr 16;8:642380. doi: 10.3389/fmed.2021.642380. eCollection 2021.
Despite significant progress in the development of treatment options, melanoma remains a leading cause of death due to skin cancer. Advances in our understanding of the genetic, transcriptomic, and morphologic spectrum of benign and malignant melanocytic neoplasia have enabled the field to propose biomarkers with potential diagnostic, prognostic, and predictive value. While these proposed biomarkers have the potential to improve clinical decision making at multiple critical intervention points, most remain unvalidated. Clinical validation of even the most commonly assessed biomarkers will require substantial resources, including limited clinical specimens. It is therefore important to consider the properties that constitute a relevant and clinically-useful biomarker-based test prior to engaging in large validation studies. In this review article we adapt an established framework for determining minimally-useful biomarker test characteristics, and apply this framework to a discussion of currently used and proposed biomarkers designed to aid melanoma detection, staging, prognosis, and choice of treatment.
尽管在治疗方案的开发方面取得了重大进展，但黑色素瘤仍然是皮肤癌导致死亡的主要原因。我们对良性和恶性黑素细胞肿瘤的基因、转录组和形态学谱的理解取得了进展，这使得该领域能够提出具有潜在诊断、预后和预测价值的生物标志物。虽然这些提出的生物标志物有可能在多个关键干预点改善临床决策，但大多数仍未得到验证。即使是最常评估的生物标志物的临床验证也将需要大量资源，包括有限的临床标本。因此，在进行大规模验证研究之前，考虑构成相关且临床有用的基于生物标志物的检测的特性非常重要。在这篇综述文章中，我们采用了一个既定的框架来确定最低限度有用的生物标志物检测特征，并将这个框架应用于讨论目前用于辅助黑色素瘤检测、分期、预后和治疗选择的生物标志物。
